Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease

Harvey D. Preisler, Joshua Epstein, Azra Raza, Nozar Azarnia, George Browman, Lynda Booker, Jack Goldberg, Arlan Gottlieb, James Brennan, Hans Grunwald, Kanti Rai, Ralph Vogler, Lee Winton, Kenneth Miller, Richard Larson

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The sensitivity of leukemic marrow cell DNA synthesis to cytosine arabinoside (araC) exposure in vitro was studied in specimens obtained from patients with acute non-lymphocytic leukemia. Cells from patients who had been treated with araC in the past were more likely to be resistant to the effect of araC on DNA synthesis than cells obtained from patients who had not been so-treated previously. Resistance to the effects of araC on DNA synthesis was associated with the failure of high-dose araC therapy to induce remissions in relapsed patients, whereas remission induction failure in previously untreated patients was not associated with araC resistance.

Original languageEnglish
Pages (from-to)1061-1068
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume20
Issue number8
DOIs
StatePublished - Aug 1984
Externally publishedYes

Fingerprint

Dive into the research topics of 'Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease'. Together they form a unique fingerprint.

Cite this